title: Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.
abstract: A number of prognostic factors affect outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL), including refractory disease and the second-line age-adjusted international prognostic index. In de novo DLBCL, the cell of orgin, as determined by expression microarray analysis or immunohistochemistry (IHC), predicts event-free survival (EFS). We evaluated the cell of origin, as well as other pathologic markers of outcome, on the repeat biopsy specimen of 88 transplantation-eligible patients undergoing ifosfamide, carboplatin, etoposide (ICE) second-line chemotherapy (SLT) followed by high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to see if were they prognostic in the salvage setting. Pretreatment clinical factors were well balanced between the cohorts. There was no significant difference in response to SLT, HDT, event-free or overall survival based on the cell of origin or any of the common pathologic markers examined. The cell of origin as determined by IHC does not predict outcome in transplantation-eligible patients with relapsed or primary refractory DLBCL.
authors.affiliation: Lymphoma and Hematology Services of the Division of Hematological Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. moskowic@mskcc.org
authors.forename: Craig H
authors.initials: CH
authors.lastname: Moskowitz
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Zelenetz
authors.forename: Tarun
authors.initials: T
authors.lastname: Kewalramani
authors.forename: Paul
authors.initials: P
authors.lastname: Hamlin
authors.forename: Simone
authors.initials: S
authors.lastname: Lessac-Chenen
authors.forename: Jane
authors.initials: J
authors.lastname: Houldsworth
authors.forename: Adam
authors.initials: A
authors.lastname: Olshen
authors.forename: Raju
authors.initials: R
authors.lastname: Chaganti
authors.forename: Stephen
authors.initials: S
authors.lastname: Nimer
authors.forename: Julie
authors.initials: J
authors.lastname: Teruya-Feldstein
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D018858:Germinal Center / Q000473:pathology*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D012008:Recurrence; D033581:Stem Cell Transplantation / Q000379:methods; D046888:Tissue Array Analysis; D014182:Transplantation, Autologous
chemical_list: D014408:Biomarkers, Tumor